ANI Pharmaceuticals Inc (ANIP): EBITDA
$202.51M
Year ended 2025-12-31
$236.16M
Trailing 12 months to 2026-06-30
+110.6%
3-year compound annual growth
+47.9%
5-year compound annual growth
+17.7%
10-year compound annual growth
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $202.51M | +196.4% | 2026-02-27, From 2025-01-01 |
| 2024-12-31 | $68.31M | -36.0% | 2026-02-27, From 2024-01-01 |
| 2023-12-31 | $106.76M | +392.2% | 2026-02-27, From 2023-01-01 |
| 2022-12-31 | $21.69M | +190.8% | 2025-02-28, From 2022-01-01 |
| 2021-12-31 | $7.46M | -73.9% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $28.62M | -53.1% | 2023-03-09, From 2020-01-01 |
| 2019-12-31 | $60.96M | -11.8% | 2022-03-15, From 2019-01-01 |
| 2018-12-31 | $69.10M | +22.8% | 2021-03-11, From 2018-01-01 |
| 2017-12-31 | $56.26M | +32.6% | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | $42.42M | +7.1% | 2019-02-27, From 2016-01-01 |
| 2015-12-31 | $39.60M | +65.8% | 2018-02-27, From 2015-01-01 |
| 2014-12-31 | $23.88M | n/m | 2017-03-02, From 2014-01-01 |
| 2013-12-31 | $2.01M | +282.5% | 2016-02-23, From 2013-01-01 |
| 2012-12-31 | $525.0K | n/a | 2014-02-28, From 2012-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| ANI Pharmaceuticals Inc (ANIP) | 2025-12-31 | $202.51M | +196.4% |
| Arrowhead Pharmaceuticals, Inc. (ARWR) | 2025-09-30 | $120.55M | n/m |
| Madrigal Pharmaceuticals, Inc. (MDGL) | 2025-12-31 | -$298.59M | n/m |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $45.95M | -66.6% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $195.90M | n/m |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $110.21M | n/m |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $29.28M | -81.9% |
| Prestige Consumer Healthcare Inc. (PBH) | 2026-03-31 | $340.68M | -7.2% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $78.78M | n/m |
Compare ANIP, ARWR, MDGL, CORT side by side · Screen every company in Pharmaceutical Preparations ↗